公开(公告)号：US20170183373A1

公开(公告)日：2017-06-29

申请号：US15461075

申请日：2017-03-16

申请人： MERCK SHARP & DOHME CORP. ,  IONIS PHARMACEUTICALS, INC.

发明人： Balkrishen Bhat ,  Anne B. Eldrup ,  Thazha P. Prakash ,  Phillip Dan Cook ,  David B. Olsen ,  Steven S. Carroll ,  Malcolm MacCoss

IPC分类号： C07H19/10 ,  C07H19/06

CPC分类号： C07H19/10 ,  A61K9/4858 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07H17/02 ,  C07H19/06 ,  C07H19/16 ,  C07H19/207 ,  Y02P20/582

摘要： The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

公开(公告)号：US20140336222A1

公开(公告)日：2014-11-13

申请号：US14339925

申请日：2014-07-24

申请人： Merck Sharp & Dohme Corp.

发明人： Stephane L. Bogen ,  Yao Ma ,  Yaolin Wang ,  Brian Robert Lahue ,  Latha G. Nair ,  Manami Shizuka ,  Matthew E. Voss ,  Margarita Kirova-Snover ,  Weidong Pan ,  Yuan Tian ,  Bheemashankar A. Kulkarni ,  Craig R. Gibeau ,  Yuan Liu ,  Giovanna Scapin ,  Diane Rindgen ,  Ronald J. Doll ,  Timothy J. Guzi ,  Danny J. Hicklin ,  Amin Nomeir ,  Cynthia Seidel-Dugan ,  Gerald W. Shipps, JR. ,  Malcolm MacCoss

IPC分类号： C07D401/14 ,  C07D409/14

CPC分类号： C07D401/14 ,  C07D409/14

摘要： The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

摘要翻译： 本发明提供本文所述的式1的化合物或其药学上可接受的盐，溶剂合物或酯。 该化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的方法。